Correlation Between Arcus Biosciences and Protagonist Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Arcus Biosciences and Protagonist Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Arcus Biosciences and Protagonist Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Arcus Biosciences and Protagonist Therapeutics, you can compare the effects of market volatilities on Arcus Biosciences and Protagonist Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Arcus Biosciences with a short position of Protagonist Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Arcus Biosciences and Protagonist Therapeutics.

Diversification Opportunities for Arcus Biosciences and Protagonist Therapeutics

0.22
  Correlation Coefficient

Modest diversification

The 3 months correlation between Arcus and Protagonist is 0.22. Overlapping area represents the amount of risk that can be diversified away by holding Arcus Biosciences and Protagonist Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Protagonist Therapeutics and Arcus Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Arcus Biosciences are associated (or correlated) with Protagonist Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Protagonist Therapeutics has no effect on the direction of Arcus Biosciences i.e., Arcus Biosciences and Protagonist Therapeutics go up and down completely randomly.

Pair Corralation between Arcus Biosciences and Protagonist Therapeutics

Given the investment horizon of 90 days Arcus Biosciences is expected to generate 1.31 times more return on investment than Protagonist Therapeutics. However, Arcus Biosciences is 1.31 times more volatile than Protagonist Therapeutics. It trades about 0.14 of its potential returns per unit of risk. Protagonist Therapeutics is currently generating about -0.25 per unit of risk. If you would invest  1,456  in Arcus Biosciences on September 25, 2024 and sell it today you would earn a total of  135.00  from holding Arcus Biosciences or generate 9.27% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Arcus Biosciences  vs.  Protagonist Therapeutics

 Performance 
       Timeline  
Arcus Biosciences 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Arcus Biosciences are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady basic indicators, Arcus Biosciences may actually be approaching a critical reversion point that can send shares even higher in January 2025.
Protagonist Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Protagonist Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's technical and fundamental indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Arcus Biosciences and Protagonist Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Arcus Biosciences and Protagonist Therapeutics

The main advantage of trading using opposite Arcus Biosciences and Protagonist Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Arcus Biosciences position performs unexpectedly, Protagonist Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Protagonist Therapeutics will offset losses from the drop in Protagonist Therapeutics' long position.
The idea behind Arcus Biosciences and Protagonist Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Other Complementary Tools

Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.